Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 6.31M | 5.32M | 4.24M | 1.53M | 1.02M | 719.52K | Gross Profit |
| 4.23M | 3.69M | 3.06M | 832.52K | 299.88K | -6.40K | EBIT |
| -10.95M | -11.68M | -10.31M | -11.52M | -11.67M | -9.47M | EBITDA |
| -9.51M | -11.68M | -9.93M | -11.52M | -11.67M | -9.25M | Net Income Common Stockholders |
| -3.25M | -7.18M | -6.25M | -9.11M | -9.04M | -6.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 30.84M | 20.61M | 24.82M | 11.02M | 16.33M | 20.44M | Total Assets |
| 40.04M | 26.62M | 29.61M | 37.90M | 19.33M | 23.17M | Total Debt |
| 657.93K | 689.69K | 562.30K | 507.56K | 621.72K | 500.89K | Net Debt |
| -30.18M | -19.92M | -24.26M | -10.51M | -15.71M | -19.94M | Total Liabilities |
| 20.40M | 22.08M | 23.46M | 27.99M | 2.46M | 2.27M | Stockholders Equity |
| 19.64M | 4.53M | 6.15M | 9.90M | 16.87M | 20.90M |
| Cash Flow | Free Cash Flow | ||||
| -8.06M | -7.45M | 13.96M | -6.80M | -4.82M | -5.31M | Operating Cash Flow |
| -7.34M | -6.51M | 14.59M | -6.26M | -4.63M | -5.26M | Investing Cash Flow |
| -733.05K | -942.02K | -631.56K | -535.02K | -188.52K | -55.20K | Financing Cash Flow |
| 19.29M | 3.24M | -164.61K | 1.49M | 709.15K | 14.52M |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
50 Neutral | AU$331.35M | ― | -524.68% | ― | 322.26% | -53.98% | |
48 Neutral | AU$308.52M | ― | -29.77% | ― | 6.07% | 59.09% | |
43 Neutral | AU$83.84M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$110.99M | ― | -46.65% | ― | 96.20% | 80.90% | |
40 Underperform | AU$89.97M | ― | -85.35% | ― | 315.11% | 51.16% |
Orthocell Ltd Corporate Events
Orthocell Limited has received regulatory approval to commence sales of its flagship nerve repair product, Remplir™, in Hong Kong, a strategically important market in the Asia Pacific region. This approval, granted ahead of schedule, adds to Orthocell’s growing portfolio of approvals in the US, Canada, Australia, New Zealand, Singapore, and Thailand, with further applications planned for the EU and UK. The company is leveraging external distributors to penetrate new markets while focusing internal resources on the US market. With a strong cash position and no debt, Orthocell is well-positioned to expand its commercial footprint and increase revenues.
Orthocell Ltd has rapidly expanded its US distribution network for its nerve repair product, Remplir™, appointing 12 distributors across 21 states, surpassing its initial target. This strategic expansion, following FDA clearance, is expected to significantly boost the company’s revenue and market penetration in the US$1.6 billion nerve repair market, leveraging experienced distributors and internal sales teams to drive growth.
Orthocell Limited has received regulatory approval from Health Canada to sell its nerve repair product, Remplir™, in the Canadian market, which is valued at US$75 million. This approval expands the total addressable market for Remplir to US$1.8 billion, following recent approvals in the US and Thailand, and existing approvals in Australia, New Zealand, and Singapore. The company plans to appoint local distributors in Canada to drive sales, with first sales expected in the second half of 2025. Orthocell is well-funded with A$31.7 million in cash reserves, positioning it to capitalize on these new market opportunities and continue its global expansion strategy.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development that could impact the company’s market positioning and stakeholder interests, as regulatory approvals are crucial for product commercialization and market expansion.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development for the company, potentially impacting its market position and stakeholder interests as it awaits the formal announcement.
Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.
Orthocell Limited has appointed its first four US distributors for its nerve repair product, Remplir™, following its recent FDA 510(k) clearance. This strategic move allows Orthocell to enter the US$1.6 billion US nerve repair market, with initial sales expected soon. The company plans to expand its distributor network to approximately 10 by mid-2025, covering around 25 states, to accelerate market penetration and revenue growth. Orthocell’s strong financial position and existing inventory support its US rollout, positioning it well for success in the competitive nerve repair industry.
Orthocell Limited has achieved a significant milestone with the US FDA 510(k) clearance for its nerve repair product, Remplir™, positioning the company to enter the lucrative US$1.6 billion nerve repair market. This clearance is expected to drive a substantial increase in revenue as the company has prepared logistics and sales pathways for its US launch. Additionally, Orthocell reported strong quarterly revenue growth, maintaining a robust cash position, and is expanding its market reach with regulatory applications in Canada and Thailand. The company’s inclusion in the S&P/ASX All Ordinaries Index further underscores its growing market presence.
Orthocell Limited has received regulatory approval from Brazil’s ANVISA for its dental regeneration product, Striate+, marking its first market authorization in Latin America. This approval is a strategic milestone for Orthocell, as Brazil represents a significant market opportunity and serves as a gateway for further expansion into Latin American countries. The approval follows the recent US FDA clearance for another product, Remplir, highlighting the company’s successful global commercialization efforts. With a strong balance sheet and a robust distribution partnership with BioHorizons, Orthocell is well-positioned to capitalize on the estimated US$735 million global market opportunity for Striate+, targeting a 20% market share.
Orthocell Limited announced the US FDA 510(k) clearance for its Remplir nerve repair product, marking a significant milestone for the company. This clearance is expected to enhance Orthocell’s market positioning in regenerative medicine, potentially benefiting stakeholders by expanding the product’s availability and application in the US market.
Orthocell Ltd has received US FDA 510(k) clearance for its nerve repair product, Remplir, allowing it to enter the US$1.6 billion US nerve repair market. This regulatory milestone is expected to significantly boost the company’s revenue and drive it towards profitability. Orthocell has prepared for this expansion with established logistics and sales pathways, a manufacturing facility capable of producing 100,000 units annually, and a strong cash reserve to support its US rollout and further market growth. The company aims to capture a meaningful market share without needing to displace existing dominant products, leveraging its proprietary manufacturing technology and strategic US commercial strategy.
Orthocell Limited has requested a trading halt on its securities pending an announcement regarding the results of its US FDA 510(k) clearance application. This clearance is crucial for the company as it seeks to commence commercial distribution in the US market, potentially impacting its market positioning and stakeholder interests.
Orthocell Limited announced that its CEO, Paul Anderson, will present at the HealthInvest 2025 conference in Sydney, highlighting the company’s progress and strategic initiatives. The presentation will include an update on the US FDA application for the Remplir nerve repair product, which signifies a critical step in Orthocell’s expansion efforts and could enhance its market positioning in regenerative medicine.
Orthocell Limited has announced the successful launch and first sales of its dental guided bone and tissue regeneration product, Striate+™, in Germany, Austria, and Switzerland, marking a significant step in its European market expansion. This move, facilitated by their distribution partner BioHorizons, is expected to rapidly increase sales and revenue, with the company targeting a 20% share of the over A$1 billion global market. The product’s strong performance, backed by a 98.6% success rate in clinical studies, and positive feedback from dental surgeons, positions Orthocell for further growth, particularly with anticipated regulatory approval in Brazil within three months.
Orthocell Limited has received regulatory approval from Singapore’s Health Sciences Authority for its dental membrane product, Striate+, marking a significant milestone in its global expansion strategy. This approval not only validates the quality of Orthocell’s products but also positions the company to capitalize on Singapore as a strategic hub for further ASEAN market penetration. With a strong balance sheet and robust sales growth driven by positive clinical feedback, Orthocell is well-positioned to increase its market share in the AU$1 billion global market opportunity, targeting a 20% share.
Orthocell Ltd has announced the issuance of 26,783 unquoted securities under an employee incentive scheme. This move is part of the company’s strategy to retain key talent and align employee interests with organizational goals, potentially strengthening its position in the competitive biotechnology market.